US · LNAI
Lunai Bioworks Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Los Angeles, CA 90067
- Website
- renovarogroup.com
Price · as of 2025-06-30
$0.32
Market cap 6.59M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $78.80 | ||||
| 2022 | $20.60 | ||||
| 2023 | $32.00 | ||||
| 2024 | $6.21 | ||||
| 2025 | $2.07 |
AI valuation
Our deep-learning model estimates Lunai Bioworks Inc.'s (LNAI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.32
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LNAI | Lunai Bioworks Inc. | $0.32 | 6.59M | — | — | — | — | -0.19 | -1.60 | — | -2.38 | -1.04 | -1.24 | 0.00% | — | — | -321.81% | -29.94% | -207.76% | -0.48 | -25.56 | 0.04 | 0.02 | -0.55 | 1846.00% | — | -2868.00% | -23.05% | -0.27 | -12.71% | 0.00% | 0.00% | 0.00% | -2.36 | -5.57 | — | -97.67 |
| ANL | Adlai Nortye Ltd. | $7.86 | 245.52M | +169% | — | — | — | -0.47 | 0.97 | — | 0.19 | — | 0.97 | 0.00% | — | — | -98.90% | -2580.88% | -51.49% | 1.07 | -28.22 | 1.41 | 1.37 | 0.70 | -6829.00% | -10000.00% | -855.00% | -211.30% | -1.14 | -2444.23% | 0.00% | 0.00% | 0.00% | 0.17 | 0.17 | — | -10.34 |
| APLM | Apollomics, Inc. | $20.21 | 22.3M | +737% | +1,097% | — | +18,417% | -0.11 | 1.22 | 29.90 | 0.07 | — | 1.89 | 100.00% | -21280.81% | -27201.01% | -233.67% | -2034.57% | -157.28% | 0.20 | -235.40 | 1.39 | 1.34 | 0.21 | -7724.00% | -7588.00% | -3343.00% | -485.92% | -3.88 | -1389.04% | 0.00% | 0.00% | 0.00% | 0.07 | 0.10 | -14.54 | -84.82 |
| BLRX | BioLineRx Ltd. | $2.83 | 12.31M | +2,367% | — | — | — | -27.55 | 18.87 | 8.78 | 63.67 | — | 84.33 | 67.99% | -70.52% | -31.86% | -69.11% | 441.68% | -17.93% | 1.12 | -2.23 | 1.76 | 1.52 | 1.18 | -8723.00% | 50292.00% | 9178.00% | -17.29% | -2.85 | 950.70% | 0.00% | 0.00% | 1.08% | -12.22 | -5.68 | 8.62 | -9.02 |
| ERNA | Ernexa Therapeutics Inc. | $0.29 | 2.24M | +35,680% | +510% | — | — | -2.77 | 72.62 | 212.25 | -3.39 | — | -360.15 | 83.51% | -2693.13% | -7652.75% | -2264.31% | -84.37% | -163.74% | 0.40 | -2.32 | 0.80 | 0.74 | 0.03 | -6152.00% | 75588.00% | -2067.00% | -13.12% | -5.39 | -87.22% | 0.00% | 0.00% | 28.59% | -7.81 | -7.56 | 210.46 | -50.59 |
| GOVX | GeoVax Labs, Inc. | $1.60 | 1.62M | — | +969% | — | — | -0.35 | 1.76 | 2.24 | -0.14 | — | 1.78 | 97.59% | -635.83% | -631.98% | -462.31% | 4381.85% | -286.62% | 0.00 | -1176.34 | 2.55 | 1.98 | 0.22 | -5284.00% | — | -209.00% | -278.43% | -7.94 | 4303.75% | 0.00% | 0.00% | 0.00% | -0.13 | -0.14 | 0.85 | -29.47 |
| ICU | SeaStar Medical Holding C… | $2.76 | 7.7M | — | — | — | — | -0.27 | -3.10 | 50.20 | -0.23 | — | -3.10 | 100.00% | -13216.30% | -18392.59% | 309.35% | 425.16% | -607.76% | -0.26 | -73.12 | 0.55 | 0.28 | 0.05 | -7809.00% | — | 5563.00% | -236.21% | -2.34 | 381.44% | 0.00% | 0.00% | 149.78% | -0.31 | -0.35 | 40.98 | -54.76 |
| LPCN | Lipocine Inc. | $9.96 | 55.3M | +2,939% | -66% | -60% | — | 2199.00 | 0.87 | 1.64 | 2.93 | — | 0.87 | 100.00% | -10.31% | 0.07% | 0.04% | 92.79% | 0.04% | 0.00 | — | 14.75 | 14.38 | 5.57 | -9995.00% | -49280.00% | -8896.00% | -7.14% | -0.81 | 113.94% | 0.00% | 0.00% | 7.81% | 2.83 | 2.49 | -0.29 | -3.70 |
| MBRX | Moleculin Biotech, Inc. | $2.39 | 2.89M | — | — | — | — | -0.18 | 0.64 | — | 0.00 | — | -0.75 | 0.00% | — | — | -135.80% | -1009.89% | -78.93% | 0.08 | — | 0.97 | 0.80 | 0.14 | -5806.00% | — | -144.00% | -619.14% | -4.45 | -905.04% | 0.00% | 0.00% | 0.00% | 0.00 | 0.00 | — | -17.68 |
| THAR | Tharimmune, Inc. | $5.12 | 202.4M | — | — | — | — | -0.16 | 1.51 | — | 0.13 | — | 1.51 | 0.00% | — | — | -233.69% | 613.15% | -166.32% | 0.00 | -908.64 | 1.54 | 1.47 | 0.29 | -9121.00% | — | 4934.00% | -553.30% | -4.52 | 537.61% | 0.00% | 0.00% | 0.00% | 0.13 | 0.15 | — | -24.00 |
About Lunai Bioworks Inc.
A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.
- CEO
- David H. Weinstein
- Employees
- 29
- Beta
- 0.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.32) − 1 = — (DCF, example).